TLP
Tri Locum Partners Portfolio holdings
AUM
$330M
This Quarter Return
+17.76%
1 Year Return
+35.44%
3 Year Return
+388.28%
5 Year Return
–
10 Year Return
–
AUM
$351M
AUM Growth
+$351M
(+44%)
Cap. Flow
+$99.6M
Cap. Flow
% of AUM
28.41%
Top 10 Holdings %
Top 10 Hldgs %
55.99%
Holding
72
New
20
Increased
10
Reduced
9
Closed
31
Top Buys
| 1 |
Biogen
BIIB
|
$24.2M |
| 2 |
Neurocrine Biosciences
NBIX
|
$20.9M |
| 3 |
Regeneron Pharmaceuticals
REGN
|
$20.7M |
| 4 |
GSK
GSK
|
$12.1M |
| 5 |
Eli Lilly
LLY
|
$11.5M |
Top Sells
| 1 |
CCXI
ChemoCentryx, Inc.
CCXI
|
$13.5M |
| 2 |
RXDX
Prometheus Biosciences, Inc. Common Stock
RXDX
|
$11.5M |
| 3 |
Evolent Health
EVH
|
$9.98M |
| 4 |
BLU
BELLUS Health Inc.
BLU
|
$9.71M |
| 5 |
TCDA
Tricida, Inc. Common Stock
TCDA
|
$7.08M |
Sector Composition
| 1 | Healthcare | 97.22% |
| 2 | Consumer Staples | 2.78% |
| 3 | Energy | 0% |
| 4 | Financials | 0% |
| 5 | Industrials | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Eli Lilly
LLY
$657B
| $34M | 9.33% | 105,170 +35,503 | +51% | +$11.5M |
|
|
2
Biogen
BIIB
$19.4B
| $24.2M | 6.64% | +90,551 | New | +$24.2M |
|
3
argenx
ARGX
$43.6B
| $22.6M | 6.22% | 64,152 -18,583 | -22% | -$6.56M |
|
|
4
Neurocrine Biosciences
NBIX
$13.8B
| $20.9M | 5.73% | +196,390 | New | +$20.9M |
|
|
5
Regeneron Pharmaceuticals
REGN
$61.5B
| $20.7M | 5.69% | +30,115 | New | +$20.7M |
|
|
CTLT
6
DELISTED
CATALENT, INC.
CTLT
| $17M | 4.67% | 235,320 +127,079 | +117% | +$9.2M |
|
7
Guardant Health
GH
$8.41B
| $15.4M | 4.22% | 285,948 +93,640 | +49% | +$5.04M |
|
8
Jazz Pharmaceuticals
JAZZ
$7.75B
| $14.2M | 3.9% | 106,528 +49,165 | +86% | +$6.55M |
|
9
Edwards Lifesciences
EW
$47.8B
| $14.1M | 3.88% | 171,082 -11,572 | -6% | -$956K |
|
10
Stevanato
STVN
$6.28B
| $13.1M | 3.59% | 771,933 -117,563 | -13% | -$1.99M |
|
|
11
GSK
GSK
$79.9B
| $12.1M | 3.31% | +409,503 | New | +$12.1M |
|
12
Bausch + Lomb
BLCO
$5.18B
| $10.7M | 2.95% | +700,525 | New | +$10.7M |
|
|
MRTX
13
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $10.6M | 2.9% | +151,534 | New | +$10.6M |
|
14
Sarepta Therapeutics
SRPT
$1.78B
| $10.6M | 2.9% | +95,445 | New | +$10.6M |
|
15
The Beauty Health Co
SKIN
$264M
| $9.73M | 2.67% | 825,109 -89,085 | -10% | -$1.05M |
|
16
Allogene Therapeutics
ALLO
$251M
| $8.47M | 2.32% | 784,133 +512,010 | +188% | +$5.53M |
|
|
RXDX
17
DELISTED
Prometheus Biosciences, Inc. Common Stock
RXDX
| $7.29M | 2% | 123,599 -194,159 | -61% | -$11.5M |
|
18
Maravai LifeSciences
MRVI
$350M
| $7.17M | 1.97% | +280,811 | New | +$7.17M |
|
19
Akero Therapeutics
AKRO
$3.74B
| $7.13M | 1.96% | +209,248 | New | +$7.13M |
|
20
Celldex Therapeutics
CLDX
$1.47B
| $6.71M | 1.84% | 238,569 +106,421 | +81% | +$2.99M |
|
21
Coherus Oncology, Inc. Common Stock
CHRS
$135M
| $6.12M | 1.68% | 636,943 +260,457 | +69% | +$2.5M |
|
22
Kezar Life Sciences
KZR
$28.9M
| $6.11M | 1.68% | 709,733 +205,391 | +41% | +$1.77M |
|
23
Astria Therapeutics
ATXS
$349M
| $5.71M | 1.57% | +631,579 | New | +$5.71M |
|
24
Natera
NTRA
$23.1B
| $5.7M | 1.56% | +129,955 | New | +$5.7M |
|
25
Teva Pharmaceuticals
TEVA
$21.1B
| $5.52M | 1.51% | +683,613 | New | +$5.52M |
|